Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
This trial is active, not recruiting.
|Condition||telangiectasia, hereditary hemorrhagic|
|Sponsor||Imperial College London|
|Trial size||100 participants|
|Trial identifier||NCT00733629, IC/CLS4|
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to culture endothelial cells from patients with HHT, to culture cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in different conditions and anticipate that DNA, mRNA and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and ALK-1. We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.
Male or female participants of any age.
Inclusion Criteria: - Patients with hereditary haemorrhagic telangiectasia and family members Exclusion Criteria: - Unable to provide informed consent
|Official title||In Vitro Studies pf Endothelial Cells Derived From HHT Patients|
|Principal investigator||Claire L Shovlin|
Call for more information